News

What is Needed to End TB and Who TB Most Affects


21 May 2018
by Working Group

Bloomberg News reported this week on how world leaders can be successful in ending TB by 2030 and the demographics that TB affects most. One article discusses multi-drug and extensive drug resistant patients as well as challenges, funding needs, and the needs for new tools to defeat TB. The other discusses TB's strong link to the most impovershed populations. To read more, please click below: 

Article 1: What will it take to finally defeat Tuberculosis 

Article 2: Who dies from TB? 

 

More News
9 Jul 2020
Earlier this week, Johnson & Johnson announced a reduction in the price for bedaquiline in low- and middle-income countries, as part of a collaboration with the Stop TB Partnership's Global Drug Facility (GDF). The immediate change in price will make bedaquiline available through the GDF at the...
18 Jun 2020
On May 21st, Antimicrbial Agents and Chemotherapy published an article on Otsuka's novel anti-tuberculosis compound, OPC-167832. This molecule, a DprE1 inhibitor, demonstrated potent bactericidal activity and exhibited significant combination effects in 2-drug combinations with delamanid,...
17 Jun 2020
On March 25th, Qurient announced the results of their Phase 2 Clinical Trial (ClinicalTrials.gov number, NCT03563599 ), which was a prospective, randomized, open-label trial for proof of concept in humans of their novel anti-tuberculosis drug, Telacebec (Q203). The trial involved 61 newly-diagnosed...